Delving into the Latest Updates on Human cord derived MSC cell (Shenzhen Wingor Bio-technology) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Mechanism

Stem cell replacements

Therapeutic Areas

Digestive System DisordersRespiratory DiseasesOther Diseases+ [3]

Active Indication

Respiratory Distress Syndrome, AcuteAcute-On-Chronic Liver FailureAcute Ischemic Stroke+ [2]

Inactive Indication-

Originator Organization

Shenzhen Wingor Bio-technology Co., Ltd.

Active Organization

Shenzhen Wingor Bio-technology Co., Ltd.

Southeast University302 Military Hospital of China

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.

Start Date30 Sep 2023

Sponsor / Collaborator

302 Military Hospital of China

[+2]

ChiCTR2100050852 / RecruitingPhase 1/2IIT

Clinical trial of HUC-MSC transfusion for ACLF patients: a multicenter, open-label, single-arm and phase I/II trial

Start Date01 Nov 2021

Sponsor / Collaborator-

100 Clinical Results associated with Human cord derived MSC cell (Shenzhen Wingor Bio-technology)

Login to view more data

100 Translational Medicine associated with Human cord derived MSC cell (Shenzhen Wingor Bio-technology)

Login to view more data

100 Patents (Medical) associated with Human cord derived MSC cell (Shenzhen Wingor Bio-technology)

Login to view more data

100 Deals associated with Human cord derived MSC cell (Shenzhen Wingor Bio-technology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Distress Syndrome, Acute	Phase 2	-	Southeast University	20 Jul 2024
Acute-On-Chronic Liver Failure	Phase 2	CN	302 Military Hospital of China	30 Sep 2023
Acute Ischemic Stroke	Phase 1	CN	Shenzhen Wingor Bio-technology Co., Ltd.	11 Aug 2023
Ulcerative colitis, active moderate	IND Approval	CN	Shenzhen Wingor Bio-technology Co., Ltd.	22 Jan 2024
Ulcerative colitis, active severe	IND Approval	CN	Shenzhen Wingor Bio-technology Co., Ltd.	22 Jan 2024